Raymond James & Associates Allogene Therapeutics, Inc. Transaction History

Raymond James & Associates

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	BUY	$10.32 - $17.28 $362,624 - $607,184	35,138 New	35,138 $379,000
Q1 2021 May 14, 2021	SELL	$25.79 - $39.02 $399,616 - $604,614	-15,495 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$25.24 - $43.45 $225,620 - $388,399	8,939 Added 136.35%	15,495 $391,000
Q3 2020 Nov 04, 2020	BUY	$32.38 - $44.96 $18,780 - $26,076	580 Added 9.71%	6,556 $247,000
Q2 2020 Jul 28, 2020	BUY	$18.39 - $54.04 $109,898 - $322,943	5,976 New	5,976 $256,000
Q2 2019 Aug 06, 2019	SELL	$25.56 - $31.09 $1.07 Million - $1.31 Million	-42,000 Closed	0 $0
Q1 2019 May 06, 2019	BUY	$24.82 - $32.54 $421,940 - $553,180	17,000 Added 68.0%	42,000 $1.21 Million
Q4 2018 Feb 11, 2019	BUY	$22.5 - $33.3 $562,500 - $832,499	25,000 New	25,000 $673,000

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.